Borys Hrinczenko

Borys Hrinczenko is a Professor of Medicine in the Division of Hematology/Oncology at Michigan State University (MSU), where he has been since 2009. Previously, he served as an Assistant Professor of Medicine at Case Western Reserve University. His research focuses on evaluating new cancer therapeutics, particularly immunotherapy agents like Durvalumab in non-small cell lung cancer.

Dr. Hrinczenko earned his M.D. from SUNY Downstate Health Sciences University in Brooklyn, completed residency at Mayo Graduate School of Medicine, and obtained a Ph.D. in Organic Chemistry from the University of Kansas. He also completed clinical and research fellowships at the National Institutes of Health (NIH), including the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases.

His research interests span clinical trials, drug development in oncology, and the application of immunotherapy in treating malignancies. Though no specific articles are listed, his work aligns with advancements in precision medicine and translational oncology.